New Appointment: Nicolas Trouche Takes Over as CEO from Thomas Kuhn at Poxel
Poxel S.A., a French pharmaceutical company, has undergone significant changes in its Board of Directors following financial difficulties. On July 31, 2025, all previous directors—Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch—resigned immediately, to be replaced by four new directors appointed by co-optation: Sophie Jacq Lapointe, Nicolas Trouche, Amit Kohli, and Alexandre Bragadir[1][3].
Sophie Jacq Lapointe, a renowned figure in the pharmaceutical industry, was appointed Chairman of the Board, succeeding Mr. Khoso Baluch. With over 20 years of experience, she brings a wealth of knowledge in oncology, immunology, neuroscience, rare diseases, and endocrinology. Her background includes leading or participating in more than 20 product launches in Europe, France, and emerging markets[1][2][3].
Ms. Lapointe has worked at prominent companies such as Roche, Sanofi, Ipsen, and biotech firm Perha Pharmaceuticals. She has also led major R&D transformation projects and advised biotech CEOs on clinical and commercial development, resulting in successful business development outcomes[1][2][3].
Nicolas Trouche, who has experience in technology start-ups and restructuring B2B industrial and commercial companies, has been appointed as the new Chief Executive Officer of Poxel S.A. (POXEL.PA)[4]. Mr. Trouche's appointment is part of a broader corporate governance overhaul agreed upon with the senior creditor, which also includes appointing a transitional CEO and implementing a short-term financial and operational transition plan. The current CEO, Thomas Kuhn, will assist during this transition period[3][4].
Amit Kohli, who operates at the intersection of science, finance, and commercialization, and Alexandre Bragadir, a Senior Investment Director at IPF Partners, were also co-opted as new directors. These co-optations are subject to ratification at the next general meeting of shareholders of the Company[1][3].
The changes in the Board of Directors are due to an agreement signed by Poxel and its directors with the senior creditor of the company. This agreement aims to support Poxel’s financial and operational continuity, as the company recently underwent insolvency declaration and filed for reorganization proceedings before the Court for Economic Activities of Lyon[3][4].
In summary, the new board members were brought in to guide Poxel through its restructuring with leaders experienced in pharmaceutical industries and business turnaround, particularly Sophie Jacq Lapointe as Chairman, reflecting a strategic move to stabilize and revitalize the company amid financial restructuring[1][3][4].
[1] Poxel S.A. [2] Sophie Jacq Lapointe [3] Les Echos [4] Reuters
- Sophie Jacq Lapointe, a seasoned professional in the pharmaceutical industry, was appointed as the new Chairman of Poxel S.A., bringing her extensive knowledge in various sectors such as oncology, immunology, neuroscience, rare diseases, and endocrinology to help guide the company through its financial and operational restructuring.
- Nicolas Trouche, with his expertise in technology start-ups and restructuring B2B industrial and commercial companies, was appointed as the new Chief Executive Officer of Poxel S.A., a move strategically made to support the company's financial and operational continuity as it navigates its reorganization proceedings.
